UB Paderborn / Katalog / Suche / in CDI

1 – 18 von 18

Sortiert nach

Two Phase 3 Trials of Baricitinib for Alopecia Areata

The New England journal of medicine, 2022-05, Vol.386 (18), p.1687-1699

2022

Volltextzugriff (PDF)

Oritavancin Population Pharmacokinetics in Healthy Subjects and Patients with Complicated Skin and Skin Structure Infections or Bacteremia

Antimicrobial Agents and Chemotherapy, 2009-10, Vol.53 (10), p.4422-4428

2009

Volltextzugriff (PDF)

Dermatologist and Patient Perceptions of Treatment Success in Alopecia Areata and Evaluation of Clinical Outcome Assessments in Japan

Dermatology and therapy, 2021-04, Vol.11 (2), p.433-447

2021

Volltextzugriff (PDF)

Visualizing Severity of Alopecia Tool (SALT) scores in the clinical setting using patient images from a clinical trial

JEADV clinical practice, 2024-06, Vol.3 (2), p.528-535

2024

Volltextzugriff (PDF)

Recognizing and managing severe sepsis: a common and deadly threat

Southern medical journal (Birmingham, Ala.), 2007-06, Vol.100 (6), p.594

2007

Volltextzugriff (PDF)

Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study

Journal of the American Academy of Dermatology, 2021-10, Vol.85 (4), p.847-853

2021

Volltextzugriff (PDF)

Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials

British journal of dermatology (1951), 2023-02, Vol.188 (2), p.218-227

2023

Volltextzugriff (PDF)

Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)

American journal of clinical dermatology, 2023-05, Vol.24 (3), p.443-451

2023

Volltextzugriff (PDF)

26158 The patient-reported burden of alopecia areata by current severity: A real-world study in the US

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB86-AB86

2021

Volltextzugriff (PDF)

26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB85-AB85

2021

Volltextzugriff (PDF)

Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis

The American journal of surgery, 2004-09, Vol.188 (3), p.212-220

2004

Volltextzugriff (PDF)

Continuous infusions of lorazepam, midazolam, and propofol for sedation of the critically ill surgery trauma patient: A prospective, randomized comparison

Critical care medicine, 1999-11, Vol.27 (11), p.2454-2458

1999

Volltextzugriff (PDF)

Patient Noncompliance with Hormone Replacement Therapy: A Nationwide Estimate Using a Large Prescription Claims Database

Menopause (New York, N.Y.), 1998, Vol.5 (4), p.226-229

1998

Volltextzugriff (PDF)

SURGICAL/TRAUMA PATIENTS RECEIVING DROTRECOGIN ALFA (ACTIVATED) IN CLINICAL PRACTICE HAVE OUTCOMES SIMILAR TO PATIENTS IN PROWESS: 520

Critical care medicine, 2004-12, Vol.32 (Supplement), p.A145

2004

Volltextzugriff (PDF)

Safety of Drotrecogin Alfa (Activated) in Surgical Patients with Severe Sepsis

Surgical infections, 2004-09, Vol.5 (3), p.253-259

2004

Volltextzugriff (PDF)

CONTINUOUS INFUSIONS OF LORAZEPAM, MIDAZOLAM, AND PROPOFOL FOR SEDATION OF THE CRITICALLY-ILL SURGERY TRAUMA PATIENT: A PROSPECTIVE. RANDOMIZED, COMPARISON

Critical care medicine, 1999-01, Vol.27 (Supplement), p.167

1999

Volltextzugriff (PDF)

Static and Dynamic Assessment of Biomarkers in Surgical Patients with Severe Sepsis

Surgical infections, 2004-09, Vol.5 (3), p.261-268

2004

Volltextzugriff (PDF)

P-7: Patient Compliance with Hormone Replacement Therapy

Menopause (New York, N.Y.), 1997, Vol.4 (4), p.252

1997

Volltextzugriff (PDF)

1 – 18 von 18

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(18)
Mit Volltextzugriff
(16)

Publikationsform

Artikel
(18)

Sprache

Englisch
(18)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(11)
Life Sciences & Biomedicine
(11)
Science & Technology
(11)
Adult
(7)
Dermatology
(6)
Female
(6)
Male
(5)
Treatment Outcome
(5)
Alopecia Areata - Drug Therapy
(4)
Biological And Medical Sciences
(4)
Hair Loss
(4)
Janus Kinase Inhibitors - Adverse Effects
(4)
Medical Sciences
(4)
Middle Aged
(4)
Alopecia
(3)
Alopecia Areata
(3)
Baldness
(3)
General & Internal Medicine
(3)
Retrospective Studies
(3)
Risk Assessment
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Two Phase 3 Trials of Baricitinib for Alopecia Areata

Oritavancin Population Pharmacokinetics in Healthy Subjects and Patients with Complicated Skin and Skin Structure Infections or Bacteremia

Dermatologist and Patient Perceptions of Treatment Success in Alopecia Areata and Evaluation of Clinical Outcome Assessments in Japan

Visualizing Severity of Alopecia Tool (SALT) scores in the clinical setting using patient images from a clinical trial

Recognizing and managing severe sepsis: a common and deadly threat

Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study

Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials

Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)

26158 The patient-reported burden of alopecia areata by current severity: A real-world study in the US

26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study

Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis

Continuous infusions of lorazepam, midazolam, and propofol for sedation of the critically ill surgery trauma patient: A prospective, randomized comparison

Patient Noncompliance with Hormone Replacement Therapy: A Nationwide Estimate Using a Large Prescription Claims Database

SURGICAL/TRAUMA PATIENTS RECEIVING DROTRECOGIN ALFA (ACTIVATED) IN CLINICAL PRACTICE HAVE OUTCOMES SIMILAR TO PATIENTS IN PROWESS: 520

Safety of Drotrecogin Alfa (Activated) in Surgical Patients with Severe Sepsis

CONTINUOUS INFUSIONS OF LORAZEPAM, MIDAZOLAM, AND PROPOFOL FOR SEDATION OF THE CRITICALLY-ILL SURGERY TRAUMA PATIENT: A PROSPECTIVE. RANDOMIZED, COMPARISON

Static and Dynamic Assessment of Biomarkers in Surgical Patients with Severe Sepsis

P-7: Patient Compliance with Hormone Replacement Therapy

Suchergebnisse filtern